Gastric Cancer, Type 2 Diabetes
Conditions
Keywords
Diabetes, Gastric cancer, Gastric bypass
Brief summary
Gastric bypass improves glycemic levels in type 2 diabetes. However, the efficacy may be varied by different gastric-small intestine reconstruction used in the procedure. There are reports that Roux en Y reconstruction may give a better result. The purpose of this study is to compare Roux en Y and Billroth II reconstruction in patients with gastric cancer comorbid with type 2 diabetes.
Detailed description
Type 2 diabetes may cause severe complications such as nephropathy and retinopathy. Additionally, it is associated with increased risk for cardiovascular events and diseases. Surgical intervention with gastric bypass has been shown to attenuate glycemic levels in obese patient comorbid with type 2 diabetes. However, since gastric bypass is not a standard procedure, surgical protocol including stomach and small intestine reconstruction may be varied. The investigators and others have found that stomach and small intestine reconstruction may affect the efficacy of diabetic treatment. In this study, the investigators will compare the efficacy of Billroth II and Roux en Y reconstruction on glycemic control in stomach cancer patients with type 2 diabetes. Both Billroth II and Roux en Y are used in stomach-small intestine reconstruction after subtotal gastrectomy. No differences in postoperative outcomes and quality of life have been reported in Billroth II and Roux en Y reconstruction.
Interventions
PROCEDUREStomach-small intestine reconstruction
Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
Sponsors
feng Zheng
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with Type 2 diabetes 2. Diagnosed with gastric cancer
Exclusion criteria
1. Type 1 diabetes 2. Unresectable cancers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glycemic control | 1 year after surgery | 1. Fasting and postprandial glycemic levels, HbA1C 2. Number of anti-diabetic drugs 3. Dosage of anti-diabetic drugs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nutritional status assessment | 1 year after surgery | 1. Body mass index 2. Anthropometric analysis 3. Plasma concentrations of albumin, pre-albumin, transferrin,and CRP |
Countries
China
Contacts
Primary ContactYu Wang, M.D
Backup ContactZhongdong Zhou, M.D
Outcome results
None listed